Class in: Economy, environment, science and technology, health
Theme : Venture capital
NORWALK, Conn., Oct. 31, 2023 /CNW/ – LifeSpan Vision Ventures, a biotechnology investment firm focused on the longevity sector, today announced an investment in NaNotics LLC. This preclinical-stage biopharmaceutical company is developing NaNots™, new subtractive nanoparticles that treat diseases by capturing and eliminating pathogenic molecules from the blood. NaNots™ are differentiated from traditional pharmacotherapies by their ability to reduce soluble targets without interacting with membrane forms of the same target, a feat generally beyond the reach of conventional drugs.
The Company is advancing a pipeline of NaNots targeting oncology and inflammatory markers associated with multiple diseases that have significant unmet medical needs. In addition, she announced research collaborations with the Mass General Cancer Clinic at Mass General Hospital and the Mayo Clinic to further improve their therapies for specific oncology targets.
HarryRobb, analyst at LifeSpan Vision Ventures, said: “With our first investment in nanomedicine, we are partnering with NaNotics, a California-based biopharmaceutical company focused on reducing soluble targets from the blood to treat a range of diseases – and possibly aging too.” So. The company is supported by a dedicated and highly experienced team committed to transforming medicine from a cell-based to a signal-based approach. This is a great opportunity to expand treatment options and we see great potential in their transformative therapies that will have a significant impact on patient outcomes.
LouHawthorne, CEO of NaNotics and creator of NaNots, said: Lifespan Vision Ventures is an ideal investor for us for reasons beyond capital. Lifespan Vision Ventures recognizes that aging may be driven by soluble factors that also cause or provoke FDA-recognized diseases, and NaNots can treat both conditions. This provides a viable path to FDA approval for a therapeutic platform to treat aging – which is not recognized by the FDA as a disease. We look forward to collaborating with Lifespan Vision Ventures to develop and commercialize therapeutic products to treat disease and improve the health of entire populations.
About NaNotics LLC
NaNotics LLC is a preclinical stage company based in Mill Valley, California. The Company is developing a pipeline of NaNots™ against a range of oncology and inflammatory targets that lead to multiple diseases and represent significant unmet medical needs.
To learn more, visit https://www.nanotics.com/
Contact: Song Schreiber, CFO: [email protected]
About LifeSpanVisionVentures
LifeSpanVisionVentures is a forward-thinking venture capital firm specializing in aging and longevity investing. Our mission is to support and accelerate the development of innovative therapies that extend healthy life expectancy, improve the quality of life as people age, and address age-related challenges. Through partnerships and strategic investments, we aim to shape a future where aging is synonymous with vitality, resilience and endless possibilities.
To learn more about LifeSpanVisionVentures, visit https://www.lifespanvisionventures.com/.
Contact: HarryRobb
Mobile: +44 7795042764
[email protected]
Photo – https://www.spamchronicles.com/wp-content/uploads/2023/10/LifeSpan-Vision-Ventures-invests-in-NaNotics-–-LeLezardcom.jpg
SOURCE LifeSpan Vision Ventures
These press releases might also interest you |
Press release sent on October 31, 2023 1:19 p.m. and distributed by:
